Martin Mackay

This profile gathers the share dealings of Martin Mackay across 4 companies, led by Alexion Pharmaceuticals Inc, Charles River Laboratories International, Inc. and SpringWorks Therapeutics, Inc. We count 40 filings; the first trade dates from 4 February 2016 and the latest from 1 July 2025.

Sales make up the whole of the open-market record (17 sales, €1.7M). The rest of the record consists of 21 share grants.

Most recently, on 2 July 2025, the filings show a transaction in SpringWorks Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.